HLS's Principal Activity is the provision of pathology, imaging and day hospitals and also facilities & support services to general practitioners, radiologists and other healthcare professionals.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+8.22%|
|vs ASX 200 (1yr)||+4.50%|
Healius Limited (HLS) is a healthcare company which provides facilities and support services to independent general practitioners, radiologists and a range of other healthcare professionals. Healius has three main businesses - Pathology, Imaging and Day Hospitals.
Incorporated Incorporated on 17 May 1994 in Victoria, Australia.
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
|DRP Features||no discount|
|Professor John Mattick||Non-Executive Director||Mar 2022||
Professor John Mattick
Professor Mattick is currently SHARP Professor of RNA Biology at UNSW Sydney. He was previously Chief Executive of Genomics England (2018-2019), and Director of the Garvan Institute of Medical Research in Sydney (2012-2018). He was appointed an Officer of the Order of Australia in 2001 for services to scientific research in the fields of molecular biology, genetics and biotechnology, particularly through the development and administration of research institutes and the Australian Genome Research Facility at the University of Queensland, where he was Foundation Director. He has over 300 research publications which have been cited over 80,000 times. He has been a member of the Australian Health Ethics Committee (AHEC) and the Research Committee of the National Health and Medical Research Council, and was involved in the development of the National Statement on the Ethical Conduct of Research involving Humans, the joint Australian Law Reform Commission (ALRC) / AHEC Commonwealth Inquiry into the Protection of Human Genetic Information, the Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology, and the ALRC Reports on Gene Patenting and Genetic Privacy. He was also Chair of the Queensland Studies Authority. He has received numerous awards including the Advance Global Impact Award (2019), the University of Texas MD Anderson Cancer Center Bertner Award for Distinguished Contributions to Cancer Research (2014), the Human Genome Organisation Chen Medal for Distinguished Academic Achievement in Human Genetics and Genomic Research (2012), the International Union of Biochemistry and Molecular Biology Medal (2011), and the inaugural Gutenberg Chair at the University of Strasbourg (2007).
|Ms Kathryn (Kate) Mary McKenzie||Non-Executive Director||Feb 2021||
Ms Kathryn (Kate) Mary McKenzie
Ms McKenzie was appointed as a Non-executive Director effective 25 February 2021. She was appointed as a member of the People & Governance Committee and as a member of the Risk Management Committee on the same date. She is a highly experienced Chief Executive Officer and Non-executive Director with experience in large change management. After starting her career in the public sector, she joined Telstra in 2004 as Group Managing Director Regulatory, Public Policy & Communications. In her 12 years at Telstra, she held a range of executive roles in strategy, marketing, products and wholesale. Prior to leaving Telstra, she was Chief Operating Officer, responsible for networks, IT, field services, property and NBN relations and delivery. In 2017 she was appointed Chief Executive Officer of Chorus, a New Zealand listed telecommunications company. She is passionate about innovation and technology, and co-founded muru-D, an incubator which has produced 44 graduating companies, with 41 still in operation; Gurrowa, a co-creation lab, and partnerships with universities, such as investment in Quantum Computing with the University of New South Wales
|Ms Jennifer (Jenny) Mitchell Macdonald||Non-Executive Director||Nov 2020||
Ms Jennifer (Jenny) Mitchell Macdonald
Ms Macdonald was appointed as a Non-executive Director and Chair of the Audit Committee effective 3 November 2020. She has a strong background in financial and general management roles across a range of industry sectors including fast moving consumer goods, resources, travel and digital media. she commenced her career with KPMG, working in the London and Melbourne offices in a number of practice areas, including audit, she spent more than ten years with that firm. After gaining experience in the resources sector, she held executive roles in the travel and tourism industries and digital media at Flight Centre and REA Group. From 2014-2016 Jenny was the Chief Financial Officer and then Interim Chief Executive Officer of Helloworld, an ASX-listed multi-channel travel company.
|Ms Alison Stephenson||Company Secretary||Aug 2019|
|Ms Sally Evans||Non-Executive Director||Aug 2018||
Ms Sally Evans
Ms Evans was appointed as a Non-executive Director in August 2018, also being appointed as a member of the Nomination and Remuneration Committee and the Risk Management Committee. On 19 August 2019, she was appointed as Chair of the newly renamed People & Governance Committee. Sally has over 30 years' experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. She has served as a Non-executive Director of Gateway Lifestyle Operations Limited.
|Dr Malcolm Parmenter||Chief Executive Officer,Managing Director||Sep 2017||
Dr Malcolm Parmenter
Chief Executive Officer,Managing Director
Dr Parmenter joined Healius as Managing Director and Chief Executive Officer (CEO) in September 2017. He has a wealth of knowledge and practical experience in the operation of frontline care, with over nine years' tenure as CEO of Independent Practitioner Network Limited (IPN), both as a listed company and under the ownership of Sonic Healthcare Limited, and subsequently two years as CEO of Sonic Clinical Services. He has a strong understanding of healthcare delivery, both in Australia and abroad, and has spent more than 20 years as a General Practitioner.
|Mr Gordon Richard Davis||Non-Executive Director||Aug 2015||
Mr Gordon Richard Davis
Mr Davis was appointed as a member of the Risk Management Committee and as Chair of the Risk Management Committee on 19 August 2019, at which time he ceased as Audit Committee Chair but remained a member of that committee. Prior to becoming a Non-executive Director, Gordon was Managing Director of AWB Limited between 2006 and 2010. He has also served in a senior capacity on various industry associations.
|Mr Charles Tilley||Company Secretary||Feb 2015|
|Mr Robert Hubbard||Non-Executive Director,Non-Executive Chairman||Dec 2014||
Mr Robert Hubbard
Non-Executive Director,Non-Executive Chairman
Mr Hubbard was a member of the Risk Management Committee up to that date. Rob Birmingham. He previously held partnership positions in the accounting, corporate finance, assurance and audit divisions of PricewaterhouseCoopers and acted as external auditor for some of Australia's largest ASX-listed companies.
|Dr Paul Francis Jones||Non-Executive Director||Nov 2010||
Dr Paul Francis Jones
Dr Jones was appointed as a Non-executive Director in November 2010. During FY 2021, he was a member of the Audit Committee (from 25 February 2021), the People & Governance Committee and the Risk Management Committee (the latter until 25 February 2021). He has over 35 years' experience in a broad range of general medical practice, including 15 years' experience in Healius Group medical centres. He originally trained at the Repatriation and General Hospital, Concord NSW and subsequently at Calvary Public Hospital, Bruce ACT. He has been a Director and Federal Councillor of the Australian Medical Association (AMA), a past President of AMA ACT and a member of the Federal AMA Council of General Practice. He was formerly a general practitioner adviser to Calvary Public Hospital and held roles as GPVMO and Director, Medical Education Program. He is a former Chair of ACT GP Workforce Working Group and was a member of the ACT Health Minister's GP Task Force in 2009
|Dean Lewsam||Chief Executive Imaging||N/A|
|John McKechnie||Chief Executive Pathology||N/A|
|Maxine Jaquet||Chief Financial Officer & Chief Operating Officer (CFO & COO)||N/A|
HLS directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|23/02/22||Gordon Davis||Buy||+8,032||$4.98||$40,000||Conversion of securities|
|23/02/22||Gordon Davis||Exercise||8,032||$4.98||$40,000||Conversion of securities|
|23/02/22||Sally Evans||Buy||+6,024||$4.98||$30,000||Conversion of securities|
|23/02/22||Sally Evans||Exercise||6,024||$4.98||$30,000||Conversion of securities|
|23/02/22||Robert Hubbard||Buy||+10,040||$4.98||$50,000||Conversion of securities|
|23/02/22||Robert Hubbard||Exercise||10,040||$4.98||$50,000||Conversion of securities|
|23/02/22||Paul Jones||Buy||+4,016||$4.98||$20,000||Conversion of securities|
|23/02/22||Paul Jones||Exercise||4,016||$4.98||$20,000||Conversion of securities|
|23/02/22||Jennifer (Jenny) Macdonald||Buy||+6,024||$4.98||$30,000||Conversion of securities|
|23/02/22||Jennifer (Jenny) Macdonald||Exercise||6,024||$4.98||$30,000||Conversion of securities|
|23/02/22||Kathryn (Kate) McKenzie||Buy||+1,004||$4.98||$5,000||Conversion of securities|
|23/02/22||Kathryn (Kate) McKenzie||Exercise||1,004||$4.98||$5,000||Conversion of securities|
|19/11/21||Kathryn (Kate) McKenzie||Issued||2,008||$4.98||$10,000||Directors' share plan|
|19/11/21||Jennifer (Jenny) Macdonald||Issued||12,048||$4.98||$60,000||Directors' share plan|
|19/11/21||Paul Jones||Issued||8,032||$4.98||$40,000||Directors' share plan|
|19/11/21||Robert Hubbard||Issued||20,080||$4.98||$100,000||Directors' share plan|
|19/11/21||Sally Evans||Issued||12,048||$4.98||$60,000||Directors' share plan|
|19/11/21||Gordon Davis||Issued||16,064||$4.98||$80,000||Directors' share plan|
|08/11/21||Malcolm Parmenter||Sell||+143,193||$4.98||($713,101)||On-market trade|
|26/10/21||Kathryn (Kate) McKenzie||Buy||+2,000||$4.99||$9,980||On-market trade|
|20/10/21||Malcolm Parmenter||Issued||101,034||$4.55||$459,704||Issue of securities|
|06/09/21||Malcolm Parmenter||Expiry||80,498||$5.00||$402,490||As advised by the company|
|06/09/21||Malcolm Parmenter||Issued||724,482||$5.00||$3,622,410||Conversion of securities|
|06/09/21||Malcolm Parmenter||Exercise||724,482||$5.00||$3,622,410||Conversion of securities|
|01/09/21||Jennifer (Jenny) Macdonald||Buy||+10,000||$4.99||$49,900||On-market trade|
|01/09/21||Jennifer (Jenny) Macdonald||Buy||+10,000||$4.98||$49,800||On-market trade|
|31/08/21||Sally Evans||Buy||+7,173||$3.485||$24,997||Conversion of securities|
|31/08/21||Sally Evans||Exercise||7,173||$3.485||$24,997||Conversion of securities|
|31/08/21||Robert Hubbard||Buy||+14,346||$3.482||$49,954||Conversion of securities|
|31/08/21||Robert Hubbard||Exercise||14,346||$3.482||$49,954||Conversion of securities|
|31/08/21||Paul Jones||Buy||+5,738||$3.485||$19,999||Conversion of securities|
|31/08/21||Paul Jones||Exercise||5,738||$3.485||$19,999||Conversion of securities|
|26/02/21||Kathryn (Kate) McKenzie||Buy||+2,500||$4.07||$10,175||On-market trade|
|25/02/21||Robert Hubbard||Buy||+7,172||$3.483||$24,977||Conversion of securities|
|25/02/21||Robert Hubbard||Exercise||7,172||$3.483||$24,977||Conversion of securities|
|25/02/21||Sally Evans||Buy||+3,586||$3.485||$12,498||Conversion of securities|
|25/02/21||Sally Evans||Exercise||3,586||$3.485||$12,498||Conversion of securities|
|10/12/20||Paul Jones||Buy||+2,869||$3.485||$9,999||Conversion of securities|
|10/12/20||Paul Jones||Exercise||2,869||$3.485||$9,999||Conversion of securities|
|10/12/20||Sally Evans||Issued||10,759||$3.485||$37,500||Directors' share plan|
|10/12/20||Robert Hubbard||Issued||21,518||$3.485||$75,000||Directors' share plan|
|10/12/20||Paul Jones||Issued||8,607||$3.486||$30,000||Directors' share plan|
|10/11/20||Jennifer (Jenny) Macdonald||Buy||+15,000||$3.51||$52,650||On-market trade|
|14/08/20||Malcolm Parmenter||Expiry||475,180||$3.18||$1,511,072||As advised by the company|
|01/07/20||Malcolm Parmenter||Exercise||26,537||$3.10||$82,264||Conversion of securities|
|01/07/20||Malcolm Parmenter||Issued||26,537||$3.10||$82,264||Conversion of securities|
|03/03/20||Malcolm Parmenter||Issued||11,081,391||$3.01||$33,354,987||Issue of options|
|25/11/19||Errol Katz||Transfer||25,000||$3.04||$76,000||Off-market transfer|
|25/11/19||Errol Katz||Transfer||25,000||$3.04||$76,000||Off-market transfer|
|13/09/19||Sally Evans||Buy||+15,000||$3.26||$48,900||On-market trade|
|19/08/19||Robert Hubbard||Buy||+25,000||$3.086||$77,150||On-market trade|
The current holdings of HLS directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Kathryn (Kate) McKenzie||23/02/2022||1,004||4,500||N/A||N/A|
|Jennifer (Jenny) Macdonald||23/02/2022||41,024||N/A||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Vinva Investment Management||28/02/2022||30,622,659||5.29|
|Australian Retirement Trust Pty Ltd||12/05/2022||30,839,249||5.33|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|12-05-22||Australian Retirement Trust Pty Ltd||30,839,249||--||5.33|
|28-02-22||Vinva Investment Management||30,622,659||--||5.29|
|22-07-21||Vinva Investment Management||31,595,448||--||5.07|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|20-09-21||Vinva Investment Management||31,595,448||5.07||--|
|09-06-21||Yarra Capital Management Limited||32,925,092||5.28||--|
|Year||Closing Price||Last Trade|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.